Rare Disease Phase 2 Deal Benchmarks — Ex-US

Understanding Rare Disease Deal Benchmarks at Phase 2

Phase 2 Rare Disease licensing deals in Ex-US territory command a median upfront payment of $228M, with values ranging from $111M at the low end to $380M for premium assets. These benchmarks reflect the risk-adjusted value of clinical-stage assets in the rare disease therapeutic area, where development costs, competitive dynamics, and market potential all factor into deal pricing.

Total deal values — including milestones for development, regulatory, and commercial achievements — range from $723M to $1.8B, with a median of $1.2B. Royalty rates for rare disease assets at this stage typically fall between 5.9% and 11.8% of net sales, reflecting the balance between licensor value contribution and licensee commercialization investment.

The Ex-US territory applies a 0.45x multiplier to base deal economics. This accounts for market size, regulatory complexity, pricing environment, and competitive landscape differences across geographies. Licensors negotiating ex-us rights should calibrate upfront expectations and milestone structures accordingly.